Squarepoint Ops LLC Purchases Shares of 109,388 AnaptysBio, Inc. $ANAB

Squarepoint Ops LLC acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 109,388 shares of the biotechnology company’s stock, valued at approximately $2,428,000.

Several other large investors have also recently modified their holdings of ANAB. Rhumbline Advisers lifted its stake in shares of AnaptysBio by 2.7% in the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock valued at $574,000 after acquiring an additional 826 shares during the last quarter. US Bancorp DE increased its stake in AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 979 shares during the period. Corton Capital Inc. lifted its position in AnaptysBio by 12.2% in the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 1,305 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares during the period. Finally, Swiss National Bank grew its holdings in shares of AnaptysBio by 9.1% in the first quarter. Swiss National Bank now owns 32,400 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 2,700 shares during the last quarter.

AnaptysBio Trading Up 1.3%

Shares of ANAB opened at $45.60 on Thursday. The firm’s 50-day moving average price is $38.13 and its 200-day moving average price is $28.60. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -16.17 and a beta of 0.29. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $47.86.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has approved a share buyback plan on Friday, November 21st that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

A number of research firms recently commented on ANAB. Truist Financial upped their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Stifel Nicolaus lowered their price objective on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Wedbush reissued an “outperform” rating and issued a $50.00 target price on shares of AnaptysBio in a research note on Monday, November 24th. Finally, Guggenheim upped their price target on AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $55.40.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.